Business Insider

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

New data demonstrate the actionability of clonoSEQ for tailoring treatment decisions in patients with MCL, CLL, MM and ALL Studies show depth of response at 10-6 provides more accurate assessment of ...
Reuters

From Data Overload to Boardroom Clarity: Snowfire AI Launches First Adaptive Decision Intelligence AI Platform, Purpose-Built for Enterprise Executives in the Age of AI

AUSTIN, TX, April 30, 2025 (EZ Newswire) -- Snowfire AI, a pioneer in decision intelligence, today announces the public launch of its patent-pending adaptive AI platform, purpose-built for executives ...
Business Wire

Aera Technology Introduces Agentic AI, Workspaces, and Control Room to Enable the Full Spectrum of Enterprise Decisions

NEW YORK--(BUSINESS WIRE)--AeraHUB ‘24 — Today at AeraHUB ‘24, the definitive Decision Intelligence event, Aera Technology announced the next evolution of the company’s Aera Decision Cloud™ platform ...
Seeking Alpha

Adaptive Biotechnologies Announces New Data at the 66th ASH Annual Meeting Highlighting Advances in MRD Testing with clonoSEQ® and Its Impact on Blood Cancer Treatment Decisions

SEATTLE, Dec. 07, 2024 (GLOBE NEWSWIRE) -- Adaptive Biotechnologies Corporation (ADPT), a commercial stage biotechnology company that aims to translate the genetics of the adaptive immune system into ...